Neopterin as a Marker of Response to Antiviral Therapy in Hepatitis C Virus Patients

Abstract EN

Predicting the efficacy of antiviral treatment of hepatitis C virus (HCV) is of importance for both patient well-being and health care expense.

The expression of interferon-stimulated genes (IFN-SGs) in the liver was suggested as a marker of response to anti-viral therapy.

IFN-SGs encode the guanosine triphosphate cyclohydrolase 1 (GTPCH), a rate-limiting enzyme of pteridines biosynthesis.

Neopterin, a stable byproduct of GTPCH-catalyzed reaction, is used as a marker of interferon-induced GTPCH activation.

We hypothesized that assessment of neopterin concentrations might predict the response to antiviral therapy.

Neopterin concentrations were evaluated in 260 HCV patients treated by pegylated interferon combined with ribavirin.

Mean and median pretreatment neopterin concentrations were lower in patients with sustained virological response than in nonresponders.

The rate of response was twofold higher among patients with pretreatment neopterin levels <16 nmol/L than in patients with neopterin levels ≥16 nmol/L, even after controlling for HCV genotype status.

Our study suggests that the pretreatment level of neopterin might be used in routine clinical practice as rapid and cost-effective marker to predict the response to antiviral therapy in HCV patients.